Liver Cancer - Drug Pipeline Analysis and Market Forecasts to 2016

Posted: Apr 29, 2010 |Comments: 0 |

GlobalData, the industry analysis specialist's new report, "Liver Cancer - Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global liver cancer market. The report identifies the key trends shaping and driving the global liver cancer market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global liver cancer sector.

GlobalData analyzed that the liver cancer market has high unmet needs in terms of both efficacy and safety. More than 90% of patients diagnosed with liver cancer are between 45 years and 85 years of age. Nexavar is the only available Food and Drug Association (FDA) approved treatment for advanced liver cancer patients. However, the median survival time in patients treated with Nexavar is only three months more than for patients treated with placebo. Moreover, Nexavar has a low safety profile. About 39% and 6% of Nexavar-treated patients reported grade 3 and grade 4 adverse reactions respectively. Therefore, the unmet need in the liver cancer market was valued at 56%. This is expected to decrease significantly between 2009 and 2016 due to the expected launch of many first-in-class and me-too drugs. The majority of the first-in-class drugs are for the early stages of liver cancer and therefore they are expected to treat patients for whom no treatment options currently exist.


This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

Scope

The scope of the report includes:
•    Annualized global liver cancer market revenues data from 2001 to 2009, forecast forward for seven years to 2016.
•    Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France and Japan.
•    Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The first-in-class molecules are primarily Tumor Necrosis Factor Alpha (TNF-alpha) inhibitors, selective estrogen receptor modulators and light activated therapies.
•    Analysis of the current and future market competition in the global liver cancer market. Key future market players covered are Bristol-Myers Squibb, Pfizer Inc., F.Hoffmann-La Roche, Bayer Ag, Onyx Pharmaceuticals, Kowa Pharmaceuticals and Celsion Corporation.  
•    Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
•    Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for future market associated with the liver cancer market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
•    Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
•    Develop business strategies by understanding the trends shaping and driving the global liver cancer market.
•    Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global liver cancer market in future.
•    Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
•    Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
•    Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
•    What's the next big thing in the global liver cancer market landscape? – Identify, understand and capitalize.

Questions and Answers

Ask
200 Characters left
Rate this Article
  • 1
  • 2
  • 3
  • 4
  • 5
  • 0 vote(s)
    Feedback
    Print
    Re-Publish
    Source:  http://www.articlesbase.com/cancer-articles/liver-cancer-drug-pipeline-analysis-and-market-forecasts-to-2016-2258747.html

    Article Tags:

    liver cancer

    ,

    drug pipeline analysis

    ,

    market forecasts

    ,

    market research report

    Visionshopsters

    This report makes a wide-ranging assessment of the marketed product portfolio, R&D pipeline, market share data, sales forecast and competitive landscape for the major players.

    By: Visionshopstersl Healthl Jul 30, 2010 lViews: 214
    Visionshopsters

    The World Market for Cancer Therapeutics and Biotherapeutics - focuses on several segments for cancer treatment.

    By: Visionshopstersl Health> Diseases and Conditionsl Mar 26, 2010

    The stem cell market is growing rapidly due to increasing regulatory approval.

    By: Ms. Sunital Business> Business Ideasl Sep 16, 2010

    Cancer translational research brings together scientists' and clinicians' suggestions to develop solutions to biomedical complications. This kind of applied research strives to offer strategies to questions surrounding the etiology, pathology, diagnosis, prevention and treating cancer.

    By: Terry Dancerl Health> Cancerl May 30, 2012

    Orbs are actually a lumpectomy or quadrantectomy combined with rotating the breast tissue or mobilize the flap into the cavity of the surgery time fill is removed. It also includes the comparative change in shape and size is doing in relation to breast and moved if necessary, does not affect the conversion of the breast. The deferred plan the reconstruction is not part of endoplasmic techniques. Both procedures are performed by specific thoracic surgeons.

    By: Omer Faroohl Health> Cancerl May 28, 2012

    What every woman fears for is losing her self confidence , losing hope and losing her personality. The term "Breast Cancer" is a very negative word and that it creates negative vibrations in her heart. So, to make her comfortable with the basics of breast cancer and to make her means any woman understand that this type of cancer is the least dangerous than all cancers and that if it is detected early then you will fight with it successfully. Causes, Symptoms, treatment, discussed in detail.

    By: Medha Srikanthl Health> Cancerl May 27, 2012
    Myra Foreman

    Mesothelioma is a rare cancer that originates in the mesothelium. The mesothelium is the protective lining that covers the body's internal organs. Mesothelioma occurs when the mesothelium cells start to divide uncontrollably.

    By: Myra Foremanl Health> Cancerl May 27, 2012

    Chemotherapy is a treatment for killing cancerous cells which is given intravenous or extra-venous to the cancer patient. Even breast cancer patients have to go through the treatment. This treatment mainly focuses on the cancerous cells that are spread in the blood stream in the whole body . If any cancerous cells are there then they are killed by the chemotherapy medicine. The medicine is very costly and it has to be taken for one or two days continuously for every 21 days .

    By: Medha Srikanthl Health> Cancerl May 25, 2012

    The global dental implants market is expected to grow from $3.2 billion in 2010 to $4.2 billion in 2015 at a CAGR of 6% from 2010 to 2015. Europe currently forms the world's largest market for dental implants with a 42% market share

    By: Sandipl Health> Dental Carel Jul 19, 2010 lViews: 397

    In pharma industry social media has emerged as an effective tool for marketing, consumer engagement, monitoring & analyzing user generated content and building & changing brand perception.

    By: Sandipl Health> Medicinel Jul 15, 2010 lViews: 203

    The changing market trends, with quick cycle of innovations have compelled market participants to clearly understand changing dynamics and focus on emerging technology and enhance market positions in terms of revenues, growth and geographical presence.

    By: Sandipl Health> Medicinel Jul 15, 2010 lViews: 223

    The global PCM market is expected to grow from $300.8 million in 2009 to $1,488.1 million in 2015, at an estimated CAGR of 31.7% from 2010 to 2015.

    By: Sandipl Technology> Electronicsl Jul 15, 2010 lViews: 108

    All the recent packaging technologies are devised keeping in mind the convenience of the consumers and the preservation and safety of food items. With rising average annual incomes, better home cooking facilities, and a shift of people towards supermarket or hypermarkets are the major factors driving this market.

    By: Sandipl Food and Beveragel Jul 15, 2010 lViews: 204

    Discuss this Article

    Author Box
    Articles Categories
    All Categories
    Quantcast